research Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas
Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
Search
for
Sort by
Research
270-300 / 1000+ results research P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
research Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata
Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
research Immunotherapy with imiquimod in cervical, vaginal, and vulvar intraepithelial lesions – a review of the literature
Imiquimod shows promise as a non-invasive treatment for certain HPV-related lesions, but more research is needed to optimize its use.
research Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in Partial Response Despite Continuous Vismodegib Treatment
Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.
research Antibody Drug Conjugates
Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
research Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.
research A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA).
Topical calcitriol is safe for preventing hair loss during chemotherapy.
research ODAC Votes No on IntraDose Injectible Cisplatin/Epinephrine Gel for Head and Neck Cancer
The committee decided not to approve the drug due to low effectiveness and high risks.
research Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
research Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
research Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
research Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
research S1‐Guideline Cutaneous Angiosarcomas – Update 2021
Cutaneous angiosarcomas require a combined treatment approach, but prognosis is generally poor.
research Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Breast cancer treatments work better with AR activation, improving results and reducing side effects.
research Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study
Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
research EXPERIENCE OF A PRIVATE HOSPITAL IN THE FEDERAL DISTRICT IN CRYOTHERAPY WITH A HYPOTHERMAL CAP FOR PATIENTS USING PACLITAXEL 80 MG/M² WEEKLY FOR 12 WEEKS
Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.
research Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata
Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
research Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research EX VIVO DRUG SENSITIVITY EVALUATION OF A RARE ZMYM2::FGFR1+ LEUKEMIA PATIENT
Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
research Case Report of a Patient With Psoriasis Vulgaris, Psoriatic Arthritis and Alopecia Universalis Successfully Treated With Tofacitinib and Methotrexate
Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
research Oral tofacitinib for the treatment of alopecia areata in pediatric patients
Tofacitinib taken by mouth helps treat hair loss in children.
research Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines
Cell proteomic footprinting enhances cancer vaccine quality by ensuring correct antigen composition.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
research Decision‐Making Regarding the Administration of Live Vaccines to Patients With a FOXN1 Heterozygous Missense Variant
Live vaccines can be safely given to infants with a FOXN1 variant if their immune function improves over time.
research 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.